Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Jonathan Miller

Internal Medicine Mobile, AL Medical Doctor

NPI 1619172285 CMS profile 978987

1700 Spring Hill Ave, Suite 100, Mobile, AL 36604

Open in the dashboard

General payments

$10,233

767 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Jonathan Miller of Mobile, AL is reported in the CMS Open Payments database as having received $10,233 across 767 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 94th percentile of Internal Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $1,218 87
2024 General $1,355 104
2023 General $1,420 102
2022 General $1,434 98
2021 General $1,843 129
2020 General $1,456 125
2019 General $1,506 122

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Jonathan Miller
  • Internal Medicine median
  • Middle half of Internal Medicine
  • National median

In program year 2025, general payments to Jonathan Miller were reported at $1,218. Among 52,115 Internal Medicine profiles paid that year, the median was $156 and the middle half received between $47 and $551.

Show as a table
Year Jonathan Miller Internal Medicine median Middle half National median
2019 $1,506 $159 $48–$570 $163
2020 $1,456 $119 $33–$402 $114
2021 $1,843 $135 $37–$521 $132
2022 $1,434 $141 $42–$496 $149
2023 $1,420 $149 $45–$519 $160
2024 $1,355 $154 $47–$537 $164
2025 $1,218 $156 $47–$551 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. AbbVie, Inc. $1,703 146 payments
  2. Novo Nordisk Inc $1,588 134 payments
  3. Pfizer Inc. $785 62 payments
  4. GlaxoSmithKline, LLC. $739 62 payments
  5. Boehringer Ingelheim Pharmaceuticals, Inc. $588 41 payments
  6. Bayer HealthCare Pharmaceuticals Inc. $530 30 payments
  7. Salix Pharmaceuticals, a division of Bausch Health US, LLC $481 28 payments
  8. AstraZeneca Pharmaceuticals LP $455 31 payments
  9. Janssen Pharmaceuticals, Inc $417 31 payments
  10. Novartis Pharmaceuticals Corporation $350 23 payments
  11. Other $2,596 179 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $10,205 765 payments
  2. Education $27 2 payments
Products named General payments · program years 2019–2025
  1. Ozempic $1,462 120 payments
  2. RYBELSUS $1,386 113 payments
  3. TRELEGY ELLIPTA $573 45 payments
  4. UBRELVY $569 34 payments
  5. XIFAXAN $559 32 payments
  6. Kerendia $530 30 payments
  7. LINZESS $473 65 payments
  8. ELIQUIS $440 36 payments
  9. VRAYLAR $426 33 payments
  10. XARELTO $385 29 payments
  11. Other $7,331 547 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 220 drugs

Part D claims

24,077

Median for Internal Medicine: 777

Drug cost

$1,837,257

Median for Internal Medicine: $73,373

Branded share of claims

21%

Median for Internal Medicine: 19.3%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Ozempic Semaglutide Brand 186 $211,643
Mounjaro Tirzepatide Brand 138 $195,513
Jardiance Empagliflozin Brand 168 $187,667
Eliquis Apixaban Brand 185 $178,238
Trulicity Dulaglutide Brand 58 $77,266
Rybelsus Semaglutide Brand 36 $73,052
Farxiga Dapagliflozin Propanediol Brand 45 $53,706
Xarelto Rivaroxaban Brand 44 $48,472
Januvia Sitagliptin Phosphate Brand 36 $47,694
Linzess Linaclotide Brand 58 $45,475

The 10 drugs with the highest cost, of 220 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 104,182 Part D prescribers listed as Internal Medicine; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 115 billing codes

Paid by Medicare

$171,292

Of which drugs: $21,541

Medicare patients

365

Average age 74

Services billed

5,248

197 women, 168 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 43%
Ischemic heart disease 39%
Diabetes 35%
Chronic kidney disease 28%
Heart failure 21%
Atrial fibrillation 21%
Cancer 19%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Vaccine for influenza for injection into muscle 90653 Office 45 45 $3,600

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 30 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
Kerendia
$197 — —
TRELEGY ELLIPTA
$151 43 —
RYBELSUS
$131 36 —
Ozempic
$131 186 —
GEMTESA
$116 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See more in the dashboard: 25 with a free account, all 30 with Patron

Records

767 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Internal Medicine in Alabama

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record